Table 3 Characteristics of the study population after IPTW
Variable | TNFi non-exposure (n = 345.35) | TNFi exposure (n = 96.88) | p value |
|---|---|---|---|
Age, years, weighted mean (SE) | 59.01 (0.78) | 57.01 (1.76) | 0.299 |
Male, weighted n (%) | 269.63 (78.03) | 78.7 (81.23) | 0.697 |
Disease duration, years, weighted mean (SE) | 3.21 (0.16) | 3.09 (0.37) | 0.758 |
Comorbidities | |||
Hypertension, weighted n (%) | 208.97 (60.48) | 53.78 (55.51) | 0.493 |
Type 2 diabetes, weighted n (%) | 88.99 (25.76) | 19.48 (20.11) | 0.378 |
Dyslipidemia, weighted n (%) | 146.79 (42.48) | 47.68 (49.22) | 0.367 |
Chronic kidney disease, weighted n (%) | 20.01 (5.79) | 3.97 (4.09) | 0.723 |
Medications | |||
Methotrexate, weighted n (%) | 38.48 (11.14) | 28.94 (29.87) | < 0.001 |
Sulfasalazine, weighted n (%) | 140.07 (40.54) | 72.91 (75.26) | < 0.001 |
Glucocorticoids, weighted n (%) | 311.36 (90.11) | 86.74 (89.53) | 0.887 |
Non-selective NSAIDs, weighted n (%) | 327.25 (94.71) | 92.76 (95.74) | 0.698 |
Selective COX-2 inhibitors, weighted n (%) | 201.59 (58.34) | 72.22 (74.55) | 0.017 |
Antiplatelet agents, weighted n (%) | 330.99 (95.79) | 96.88 (100.00) | NA |
Anticoagulants, weighted n (%) | 59.53 (17.23) | 13.15 (13.58) | 0.566 |
Statins, weighted n (%) | 322.22 (93.25) | 92.80 (95.79) | 0.392 |
ACE inhibitors or ARBs, weighted n (%) | 260.78 (75.47) | 77.90 (80.40) | 0.401 |
Beta-blockers, weighted n (%) | 221.52 (64.11) | 58.14 (60.01) | 0.565 |
SGLT2 inhibitors, weighted n (%) | 37.35 (10.81) | 11.24 (11.60) | 0.839 |
GLP1 receptor agonists, weighted n (%) | 3.09 (0.89) | 0.00 (0.00) | NA |
Recurrence, weighted n (%) | 33.60 (9.72) | 4.54 (4.69) | 0.132 |